Nadler Financial Group Inc. Has $775,000 Stake in Johnson & Johnson (NYSE:JNJ)

Nadler Financial Group Inc. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.8% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 5,305 shares of the company’s stock after selling 98 shares during the period. Nadler Financial Group Inc.’s holdings in Johnson & Johnson were worth $775,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Norges Bank acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $4,071,642,000. Wellington Management Group LLP grew its position in shares of Johnson & Johnson by 16.4% during the 4th quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company’s stock worth $3,764,852,000 after buying an additional 3,391,657 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Johnson & Johnson by 16.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,834,359 shares of the company’s stock worth $3,453,978,000 after buying an additional 3,139,499 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Johnson & Johnson by 1.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 15,945,533 shares of the company’s stock worth $2,483,532,000 after buying an additional 241,799 shares during the period. Finally, California Public Employees Retirement System grew its position in shares of Johnson & Johnson by 4.9% during the 4th quarter. California Public Employees Retirement System now owns 10,620,264 shares of the company’s stock worth $1,664,620,000 after buying an additional 498,647 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 16th. Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday, August 5th. Finally, Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Stock Up 0.6 %

JNJ traded up $0.98 during trading on Wednesday, reaching $161.14. The company had a trading volume of 1,599,304 shares, compared to its average volume of 7,287,056. The business’s fifty day moving average price is $152.89 and its 200 day moving average price is $153.09. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The company has a market cap of $387.81 billion, a P/E ratio of 10.00, a PEG ratio of 2.63 and a beta of 0.52. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $167.84.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The business had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.80 earnings per share. Equities analysts anticipate that Johnson & Johnson will post 10.07 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 3.08%. Johnson & Johnson’s payout ratio is 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.